LinkedIn has revealed the top 20 most in-demand employers among its 13 million UK-based members.
The social network for business, LinkedIn is heavily geared towards the job and career markets. The latest statistics display the way in which LinkedIn’s user demographic is focused around the professional classes. The company has already been marked out for advertisers as an aggregator of valuable consumers on the internet.
Google remains top of the list with a host of household names to follow.
Top 20 Most inDemand Employers among UK LinkedIn members
- Google (NASDAQ:GOOG) (-)
- Apple (NASDAQ:AAPL) (+5)
- BP (BP) (+2)
- Shell (NYSE: RDS.A)(-)
- John Lewis (LSE: JLH) (+3)
- Microsoft (NASDAQ: MSFT) (-)
- BBC (-5)
- HP (NYSE: HPQ) (+2)
- Unilever (NYSE: UN) (-6)
- Marks & Spencer (NYSE: MKS.L) (+2)
- ITV (LSE: ITV.L) (+7)
- Burberry (LSE: BRBY.L) (-3)
- ASOS.com (LSE: ASC.L) (+6)
- GlaxoSmithKline (LSE: GSK.L) (-3)
- Accenture (NYSE: ACN)(-)
- BAE Systems (LSE: BA.L) (+1)
- Goldman Sachs (NYSE: GS) (-4)
- Amazon (NASDAQ: AMZN)(+16)
- Carillion (LSE: CLLN) (+8)
- Amec (LSE: AMEC.L) (+24)
(Brackets () indicate stock code followed by change in position since 2012)
In This Story: GlaxoSmithKline
GlaxoSmithKline plc (GSK) is a British multinational pharmaceutical company headquartered in Brentford, England.
Established in 2000, by a merger of Glaxo Wellcome and SmithKline Beecham, GSK was the world’s sixth largest pharmaceutical company according to Forbes as of 2019, after Pfizer, Novartis, Roche, Sanofi, and Merck & Co.
GSK is the tenth largest pharmaceutical company and #296 on the 2019 Fortune 500, ranked behind other pharmaceutical companies including China Resources, Johnson & Johnson, Roche, Sinopharm, Pfizer, Novartis, Bayer, Merck, and Sanofi.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index. As of August 2016, it had a market capitalisation of £81 billion (about US$107 billion), the fourth largest on the London Stock Exchange. It has a secondary listing on the New York Stock Exchange.
The company developed the first malaria vaccine, RTS,S, which it said in 2014, it would make available for five percent above cost. Legacy products developed at GSK include several listed in the World Health Organization‘s List of Essential Medicines, such as amoxicillin, mercaptopurine, pyrimethamine, and zidovudine.
In 2012, GSK pleaded guilty to promotion of drugs for unapproved uses, failure to report safety data, and kickbacks to physicians in the United States and agreed to pay a US$3 billion (£1.9bn) settlement. It was the largest health-care fraud case to date in that country and the largest settlement by a drug company.
GlaxoSmithKline CEO on spinoff of consumer health-care business
Jim Cramer: What to watch for at GlaxoSmithKline investor day